Posts Tagged 'sglt2'

Trouble for Diabetes Drug Makers?

invokana and farxiga mdls to move forwardKnown as SGLT2 inhibitors for short, sodium glucose co-transporter 2 inhibitors are a class of drugs intended for certain individuals with Type II diabetes. The drugs prevent glucose from being absorbed in the kidneys and reduce glucose in the blood by causing it to be expelled in the urine.

Unfortunately, this relatively new class of drugs has already allegedly caused enough harm to warrant FDA action ...

continue reading...

Lopez McHugh Files Invokana Lawsuit Alleging Diabetic Ketoacidosis Injury

PHILADELPHIA (December 2015) – The national trial lawyers of Lopez McHugh have filed a lawsuit against Johnson & Johnson and its subsidiary, Janssen, alleging that its diabetes medication, Invokana®, causes patients to develop diabetic ketoacidosis.

The lawsuit (Case No. 15-12-00653) was filed in the Court of Common Pleas, Philadelphia County, and includes allegations that the manufacturers of Invokana knew that the drug could cause diabetic ketoacidosis but failed to warn doctors.

Diabetic ketoacidosis is a condition where the body produces ketones, ...

continue reading...

Invokana Maker Counters with Own SGLT2 Inhibitor Study

invokana issues report rebuttalAmid recent research linking sodium-glucose cotransporter-2 (SGLT2) inhibitors to diabetic ketoacidosis, Invokana maker Janssen Pharmaceutica has countered with its own report on the new diabetic drug. The study, published in late July by the journal Diabetes Care, claims that incidents of the potentially fatal blood condition are “rare.”

SGLT2 inhibitors are a relatively new class of type 2 diabetes drugs. They work by reducing the amount of glucose reabsorbed in the kidneys ...

continue reading...

Endocrinologists to Explore Link between SGLT2 Inhibitors and Diabetic Ketoacidosis

endocrinologists exploring sglt2 inhibitor link to ketoacidosisThe American Association of Clinical Endocrinologists (AACE) has begun looking into the possible link between sodium-glucose cotransporter-2 (SGLT2) inhibitors, an emerging class of diabetes drugs, and the severe blood condition known as diabetic ketoacidosis. According to Diabetes.co.uk, the AACE plans to hold a conference on the subject in late October.

SGLT2 inhibitors are a new type of diabetes medication approved by the U.S. Food and Drug Administration (FDA) for ...

continue reading...